CeGaT now offers the analysis of tumor mutational burden (TMB) and microsatellite instability (MSI) as a stand-alone analysis. The diagnostic portfolio of genetic tumor diagnostics is thereby expanded with a specific test for decisions on immunotherapy using checkpoint inhibition.

Immunotherapy has become an important and promising treatment option for cancer patients in recent years. Immune checkpoint inhibition is already a frequent therapy recommendation of the Molecular Tumor Board at the University Hospital in Tübingen. Its relevance to medicine and society has also been recognized by the Nobel Prize Committee, which has awarded this year’s Nobel Prize for Medicine to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.

CeGaT supports oncologists in carrying out this innovative therapy option in clinical practice. CeGaT’s TMB analysis has been available since 2017, as a part of the Somatic Tumor Panel for Treatment Decisions. Offered as a stand-alone analysis, the TMB diagnostics is now available with shorter turnaround times, improved cost-efficiency, and features our industry-leading high quality.

TMB as a predictive tumor marker for immuno-oncology

The benefit of immunotherapy using immune checkpoint inhibitors is undeniable, yet success rates still vary. Despite the same diagnosis, some groups of patients respond better to immunotherapy than others. Therefore, there is a need to identify and standardize new biomarkers for the identification of groups of patients that respond well to immunotherapy. One of these biomarkers is tumor mutation burden (TMB).

A growing number of studies are providing evidence that tumor mutational burden (TMB) is a good marker for treatment of tumor patients. It is defined as the number of somatic mutations per million base pairs (Mut/Mb). High TMB is associated with an increased response to therapy with immune checkpoint inhibitors.

High-quality determination of TMB is the basis for therapeutic decisions on checkpoint inhibition and should be regarded as part of routine diagnostics in tumor therapy.

The CeGaT TMB analysis can be requested here:

Tumor Immuno-Oncology Analysis (TMB and MSI)

For further assistance please contact our team at sales@cegat.de.